Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Zhao Weili
This study retrospectively collected the data of patients previously treated with Tafa and divided them into two coords according to different protocols received. Cohort 1 was Tafa combined treatment group, which could include Tafa combined with lenalidomide, Tafa combined with Lenalidomide plus BTK inhibitor, Tafa combined with Lenalidomide plus chemotherapy (including ADC). Cohort 2 was treated with sequential CAR T or graft after Tafa combination therapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with pathological diagnosis of DLBCL, including but not limited to non-specific DLBCL (NOS-DLBCL); Large B-cell lymphoma (THRLBCL) rich in T cells/histiocytes; EBV positive DLBCL (EBV-positive DLBCL); According to the revised REAL/WHO classification, it was grade 3b follicular lymphoma, including DLBCL component, followed by DLBCL recurrence. In addition, patients with low-grade lymphomas such as follicular lymphoma, marginal zone lymphoma, and chronic lymphocytic leukemia have histological evidence of transformation to DLBCL and subsequent recurrence
Patients who, as determined by the treating physician, would benefit from Tafa treatment
You may not be if
Known allergy or metabolic disorder to any drug in the regimen
Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period
Have a history of uncontrolled medical disease (including uncontrolled diabetes, severe heart, lung, liver, renal insufficiency), blood, endocrine system, and other malignancies
Severe mental illness
Patients deemed unsuitable for inclusion by the investigator